EnClear Therapies is a life sciences company developing device-based therapies for the treatment of neurodegenerative disease.
EnClear Therapies' mission is to halt the progression of disease and extend the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP) by removing toxic proteins that build up in the brain, significantly impacting neurodegeneration.
EnClear Therapies was founded in 2018 by Anthony DePasqua, Kevin Eggan, Kasper Roet, and William Gormley. The company is headquartered in Cambridge, Massachusetts.
EnClear’s proprietary therapeutic platform focuses on removing toxic proteins from the CSF. The company’s first products will target improving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP).
EnClear Therapies is backed by 20/20 HealthCare Partners (“20/20 HCP”), Peter Thiel, Amgen Ventures, GHS Fund (Quark Venture LP and GF Securities) and others. The company raised $10M in a Series A round on Feb 19, 2020. This brings EnClear Therapies' total funding to $12M to date.